Breye Therapeutics Publishes Groundbreaking Diabetic Retinopathy Research in Science Translational Medicine

Copenhagen (Denmark) – Golgi Neurosciences is proud to announce that its portfolio company, Breye Therapeutics, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, in collaboration with researchers at Trinity College Dublin, has published a groundbreaking study in Science Translational Medicine demonstrating the potential of oral Danegaptide as a novel treatment approach for Non-Proliferative Diabetic Retinopathy (NPDR).

Diabetic retinopathy is a leading cause of vision loss among working-age adults, with NPDR representing the majority of cases. Current treatment options are typically reserved for advanced stages of disease and often rely on repeated intravitreal injections, limiting opportunities for early intervention.

The study demonstrates that Danegaptide can protect the integrity of the inner blood-retina barrier, a key component in maintaining retinal health and preventing vascular leakage. In preclinical models of diabetic retinopathy, oral administration of Danegaptide rapidly reduced retinal vascular leakage, prevented blood-retina barrier breakdown, and reversed retinal edema, achieving efficacy comparable to established injectable therapies.

These findings support a novel therapeutic paradigm focused on preserving retinal function and addressing disease mechanisms earlier in the disease course through a non-invasive treatment approach.

The publication represents an important scientific milestone for Breye Therapeutics and further validates its innovative strategy to develop transformative therapies for retinal diseases with significant unmet medical need.

Golgi Neurosciences congratulates the Breye Therapeutics team and its academic collaborators on this significant achievement, which reinforces the company’s leadership in advancing next-generation treatments designed to protect vision and improve outcomes for patients with diabetic eye disease.

For more information see Breye Therapeutics website and Golgi Neurosciences’ Linkedin Page.